Innate Pharma S.A. (FR:IPH) has released an update.
Innate Pharma S.A. reported a strong end to 2023, showcasing positive outcomes from the TELLOMAK Phase 2 trial for Sézary syndrome and advancing their proprietary ANKET® platform with Sanofi’s licensing of a fourth NK cell engager, adding €15m to Innate’s funds. The company also highlighted the initiation of a Phase 1/2 trial for their second-generation ANKET® in B-cell Non-Hodgkin’s Lymphoma and expects to maintain their financial runway until the end of 2025, thanks to a cash position of €102.3 million.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
